Introduction
Two new species related to Candida glabrata, Candida nivariensis and Candida bracarensis have been recently proposed [1, 2] . As stated in several reports, conventional methods of classifi cation based on morphological, biochemical and physiological features have proven ineffective in accurately identifying such species [3, 4] . Although the three species are related phylogenetically, PCR-based procedures and DNA sequencing have shown that C. glabrata , C. nivariensis and C. bracarensis are sufficiently genotypically different to justify their assignment as separate species. In addition, some authors have pointed (2.2%) isolates. One of these was recovered from a pelvic abscess in a patient with perforated diverticulitis and the other two were found to be colonizing two adult oncology patients [5] .
We describe the occurrence of these new species among C. glabrata isolates in a Spanish Reference Laboratory between 2008 and 2009 and in those collected in an active population-based surveillance of candidemia that was carried out in Barcelona over a period of two years (2002 -2003) .
Material and methods

Organisms
A total of 143 clinical isolates initially identifi ed as C. glabrata were sent to the Mycology Laboratory of the Spanish National Centre for Microbiology for confi rmation and susceptibility testing. The strains were collected from 56 Spanish hospitals over a period of two years, from 2008 -2009, with each strain representing a unique isolate from a patient. The isolates were recovered from blood (61; 43.6%), biopsies and other deep sites, (46; 32.3%), and other locations (34; 23.7%).
In addition, a total of 31 strains identifi ed as C. glabrata in a prospective population-based surveillance study of candidemia conducted in Barcelona (Spain) between 2002 and 2003 were also included in this study [12] .
Candida albicans (CBS 562), C. glabrata (CBS 138), C. bracarensis (CBS10154), and C. nivariensis (CBS9984) obtained from the Centraalbureau voor Schimmelcultures (CBS; Utrecht, The Netherlands) were included for molecular comparison as type and reference strains. Sequences of C. bracarensis (GeneBank accession number AY589573.2) and C. nivariensis (GeneBank accession number GU199443.1) were employed as references in the analysis.
Species identifi cation
Isolate identifi cation was confi rmed at the Spanish Reference Mycology Laboratory by morphological, physiological and molecular methods according to routine procedures. Briefl y, for molecular identifi cation purposes, genomic DNA was directly prepared from a single yeast colony. DNA segments comprising the D1/D2 domains of the 26S ribosomal DNA and ITS1/ITS2 regions were amplifi ed and sequenced using universal primers. Further analysis was performed by comparison with ITS sequences of type and reference isolates and with those included in the database of the Mycology Department of the Spanish National Centre for Microbiology, a restricted data base including more than 6,000 sequenced microorganisms. Analyses were conducted with InfoQuest FP 4.50 software (BIO-RAD Laboratories, Madrid, Spain), using the neighbourjoining method based on the Kimura two-parameter model. C. albicans (CBS562T) was used as an out-group to root the phylograms [4, 7, 13] .
In-vitro susceptibility testing
Susceptibility studies were performed according to the EUCAST (European Committee on Antimicrobial Susceptibility Testing) reference method [14] . The antifungal agents used were amphotericin B (Sigma Aldrich Quimica S.A., Madrid, Spain), fl ucytosine (Sigma-Aldrich), fl uconazole (Pfi zer S.A., Madrid, Spain), itraconazole (Janssen S.A., Madrid, Spain), posaconazole (Schering-Plough, Kenilworth, NJ, USA), and voriconazole (Pfi zer S.A.), anidulafungin (Pfi zer S.A.), micafungin (Astellas Pharma Inc, Tokyo, Japan), and caspofungin (Merck & Co., Inc., Rahway, NJ, USA).
Results
A total of 3 (2%) isolates out of the 143 C. glabrata clinical strains sent to the Reference Laboratory in 2008 and 2009 were identifi ed as C. bracarensis by DNA sequencing . One strain was isolated in 2008 from a catheter exudate of a critically ill patient (CNM-CL-7030, Yeast Collection of Spanish National Centre for Microbiology) [4, 15] . The other two were recovered in 2009, one from a sample of pleural liquid of a patient who underwent thoracic surgery due to an oesophageal fi stula (CNM-CL-7326), and the other from blood of a patient who had a haematological disease (CNM-CL-7380). Notably, none of 143 clinical isolates that were initially identifi ed as C. glabrata were found through molecular methods to be C. nivariensis .
Results of the 2002 -2003 population-based surveillance included 31 episodes of fungemia were identifi ed as common cause of candidemia [12] . It appears that marked differences exist in species distributions and antifungal drug susceptibilities among different countries, underscoring the need for continued surveillance to monitor trends in pathogen distribution and drug susceptibilities.
The two new C. glabrata -related species appear to be rarely recovered from clinical samples. Unlike the United Kingdom, the Spanish Reference Mycology Laboratory has not reported any isolates of C. nivariensis among 1,096 yeast analyzed by molecular methods between 2008 and 2009 [4,15] and in agreement with previous studies, about 2% of the isolates were C. bracarensis [4] . The susceptibility profi le of C. bracarensis and C. nivariensis is similar to that of C. glabrata although a reduced susceptibility to azole agents and resistance in vitro to fl ucytosine have been described among the limited number of isolates whose susceptibility profi les have been reported [5, 6] .
However, results found through passive epidemiological surveillance by reference centres may be biased, as they receive uncommon species and microorganisms that are often diffi cult to identify. Results from active populationbased surveillance studies should be considered as more signifi cant as it identifi es all cases of the disease being studied regardless of the health-care setting in which it occurs. It minimizes bias resulting from the selection of only a subset of hospitals, and it enables newly-affected patient groups to be identifi ed. Results from the 2002 -2003 population-based surveillance study of candidemia in Spain showed that the two C. glabrata -related new species did not cause fungemia.
In light of their minimal occurrence, the use of molecular methods on a routine basis to distinguish the two new species from C. glabrata is not recommended for use in clinical laboratories. However, susceptibility testing must be performed, since some of the antifungal agents available may prove to be less active against these species. Periodical surveillance including molecular methods of characterization seems to be advisable, since new and cryptic species C. glabrata on the basis of conventional identifi cation procedures. This was 9% of the total of 345 episodes of candidemia that were analyzed in the study period which is equal to an average annual incidence of 0.38 cases/100,000 population [2] . Based on molecular criteria, all the isolates were identifi ed as C. glabrata as their ITS sequences completely matched that of the type strain of this species ( C. glabrata CBS 138, ATCC 2001). Neither C. nivariensis nor C. bracarensis were detected among these strains. The ITS analysis showed three main clusters, with all the clinical strains studied found to be in the same cluster ( Ͼ 99% identicality between them). The other two clusters included the reference strains of C. nivariensis and C. bracarensis which were part of these investigations for comparative purposes. Antifungal susceptibility data were consistent with those of C. glabrata reported in other studies (Table 1) [12, 15] . The MIC values found with C. bracarensis isolates were comparable with those of C. glabrata (Table 2 ), but the limited number precludes any defi nitive conclusions as to its susceptibility.
Discussion
Candidemia remains a major cause of morbidity and mortality in the health care setting. Of particular concern is the reported increase in the proportion of such infections caused by C. glabrata , a species which is associated with reduced susceptibility to azole antifungal agents [15, 16] . The occurrence of candidemia due to this species ranges between 10 and 35% according to different publications [17 -20] . Recently, data from the prospective antifungal therapy Alliance registry has been published [21] and included a total of 2,019 patients with candidemia from 23 medical centres in North America. While C. albicans was the most commonly identifi ed etiologic agent (45.6%), collectively, non-C. albicans Candida species appeared to be more frequent agents (54.4%), with 520 (26%) cases due to C. glabrata . In Spain, C. glabrata has emerged as an important nosocomial pathogen, being the fourth most have been described, in order to determine their frequency, geographical distribution and susceptibility profi les.
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